EU Clears Tecvayli Plus Daratumumab for Myeloma

The European Commission has approved the use of TECVAYLI (teclistamab) in combination with daratumumab for adults with relapsed or refractory multiple myeloma who have received at least one prior therapy. Johnson & Johnson announced the decision on 21 August 2026. The practical effect is one of position rather than novelty: teclistamab has been authorised in the EU since 2022 for heavily pretreated patients, and this extension moves the bispecific antibody into the second line, where the field has been converging.

Opinion, then decision

EU indication extensions run through a two-step machinery that is easy to elide and worth keeping straight. EMA's Committee for Medicinal Products for Human Use assesses the variation and adopts a scientific opinion; the European Commission then issues the decision that actually amends the marketing authorisation and makes it binding across the Union. For this application the committee adopted its positive opinion in late June 2026, recommending a change to the terms of the Tecvayli authorisation, and the Commission decision followed on 21 August. Between those two dates nothing is authorised, which is why sponsors announce both and why a CHMP recommendation is not a market event.

Tecvayli's underlying authorisation dates to 23 August 2022, granted initially as a conditional marketing authorisation. This variation does not disturb that history; it widens the population the product may be used in, in a defined combination.

What the trial was asked to show

MajesTEC-3 is a Phase 3 study of subcutaneous teclistamab plus daratumumab against investigator's choice of daratumumab-based standard-of-care regimens — daratumumab with dexamethasone plus either pomalidomide or bortezomib — in patients who had received one to three prior lines of therapy. The comparator matters as much as the experimental arm: this was not a single-arm study in patients out of options, which is the design that supported the original 2022 authorisation, but a randomised comparison against regimens already in routine use at that point in the disease. That is the evidentiary step an earlier-line indication generally requires.

The mechanistic rationale offered for the pairing is complementarity: daratumumab modulates the immune environment in a way that supports T-cell fitness and activation, and teclistamab, a bispecific that engages T cells against BCMA-expressing myeloma cells, depends on that T-cell compartment to work. Whether the combination's benefit in practice tracks the rationale is a question for the published trial data and the updated product information rather than the press release.

Operational consequences

• Sequencing. A bispecific authorised from the second line changes what comes after it. Programmes positioning BCMA-directed products in later lines now sit behind an authorised earlier-line option.
• Risk management. T-cell engagers carry class-specific safety obligations — step-up dosing, monitoring for cytokine release syndrome and neurological events. Moving into an earlier, larger population widens the set of centres that must be equipped for them.
• Additional monitoring. Tecvayli carries the black inverted triangle, so healthcare professionals and patients should continue to report suspected adverse reactions through national reporting systems.
• Label, not press release. The operative text is the amended summary of product characteristics published with the Commission decision; the wording of the indication, not the announcement, defines who may be treated.

What happens next

The Commission decision applies throughout the EU immediately, but availability does not follow automatically: each member state runs its own pricing and reimbursement assessment, and those timelines vary by an order of magnitude across the Union. For regulatory affairs teams the near-term items are the updated product information in the Union Register, the revised risk management plan obligations that accompany a widened population, and, for anyone running a comparator-controlled study in this setting, the question of whether the standard of care their protocol names is still the standard of care.